Visioneering Technologies, Inc.

VTI

AU000000VTI2

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 09:30:17 2024-05-05 pm EDT			5-day change	1st Jan Change
0.1 ^AUD	+4.17%		-25.93%	-60.00%

Apr. 24	Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Feb. 28	Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Visioneering Technologies, Inc. announced that it has received AUD 4.32234 million in funding from Thorney Technologies Ltd

July 10, 2019

On July 11, 2019, Visioneering Technologies, Inc. (ASX:VTI) closed the transaction. The company issued AUD 3,000,000 notes at a price of AUD 1.44078 per note for gross proceeds of AUD 4,322,340.

Latest news about Visioneering Technologies, Inc.

Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study	Jan. 18	MT
Visioneering Technologies Issues Part of Shortfall from Rights Offering	Jan. 04	MT
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call	Nov. 01
Transcript : Visioneering Technologies, Inc., Q3 2023 Earnings Call, Oct 18, 2023	23-10-18
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion	23-10-10	MT
Visioneering Technologies Appoints CEO	23-08-28	MT
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023	23-08-28	CI
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023	23-08-28	CI
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Transcript : Visioneering Technologies, Inc., Q2 2023 Earnings Call, Jul 21, 2023	23-07-20
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call	23-05-24
Transcript : Visioneering Technologies, Inc., Q1 2023 Earnings Call, Apr 20, 2023	23-04-19
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal	23-03-12	MT
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Visioneering Technologies, Inc. Announces Board Changes	22-12-19	CI
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial	22-12-07	MT
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT	22-12-06	CI
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call	22-10-26
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Transcript : Visioneering Technologies, Inc., Q2 2022 Earnings Call, Jul 20, 2022	22-07-20
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial	22-07-12	MT
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control	22-07-12	CI
Visioneering Technologies, Inc. Announces Board Changes	22-06-29	CI

Chart Visioneering Technologies, Inc.

Duration

Period

More charts

Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Glasses, Spectacles & Contact Lenses

	1st Jan change	Capi.
VISIONEERING TECHNOLOGIES, INC.	-60.00%	3.5M
ESSILORLUXOTTICA	+9.25%	98.38B
THE COOPER COMPANIES, INC.	-2.34%	18.02B
AUTEK CHINA INC.	-13.73%	2.33B
WARBY PARKER INC.	-9.29%	1.51B
PEGAVISION CORPORATION	+24.97%	1.21B
MINGYUE OPTICAL LENS CO.,LTD.	-33.83%	755M
MENICON CO., LTD.	-36.42%	744M
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-9.39%	665M
VIZIONFOCUS INC.	+28.48%	509M

Glasses, Spectacles & Contact Lenses